Loading organizations...
Key people at Augmenix, Inc..
Augmenix, Inc. is a Waltham, Massachusetts-based medical technology company that develops proprietary hydrogel products designed to reduce toxicity and improve patient outcomes during radiation oncology treatments. The organization's flagship product, the SpaceOAR System, is an injectable gel that temporarily creates space between the prostate and the rectum to protect healthy tissue during prostate cancer radiotherapy. Following its initial FDA clearance in April 2015, the enterprise established a commercial sales model providing its medical devices and consumable hydrogels directly to hospitals, urology clinics, and healthcare providers. Under the leadership of former CEO John Pedersen, the business generated approximately $50 million in annual revenue during 2018 before being acquired by Boston Scientific in October 2018 for $500 million upfront and up to $100 million in sales-based milestones. Augmenix was originally founded in 2008 by entrepreneur Amar Sawhney.
Key people at Augmenix, Inc..
Augmenix, Inc. was a privately held medical device company that developed and commercialized the SpaceOAR System, an absorbable hydrogel spacer injected between the prostate and rectum to protect the rectum from radiation damage during prostate cancer therapy.[1][2][3] It served radiation oncologists, urologists, and prostate cancer patients, addressing the problem of rectal toxicity—a common, debilitating side effect of radiotherapy—by clinically proven space creation that reduces injury and long-term complications; SpaceOAR was the first FDA-cleared prostate spacing device.[1][3][4] The company raised $62.7 million in funding, achieved ~$50 million in 2018 sales with projections to $90 million in 2019, and employed up to 140 people before its acquisition, demonstrating strong commercial momentum via expanded reimbursements and global adoption in over 30,000 patients.[1][3]
Founded in 2008 in Bedford, Massachusetts, Augmenix emerged from proprietary hydrogel technology licensed from Incept LLC, focusing initially on radiation oncology applications.[1][3] Key leadership included CEO John Pedersen, who highlighted clinical and commercial successes leading to acquisition.[3] Early traction built through FDA clearance for SpaceOAR, AMA Category I CPT code approval with support from ASTRO and AUA, and Medicare coverage expansions (e.g., Palmetto GBA in 2017), enabling rapid adoption.[1][4] By 2018, these milestones positioned Augmenix for a transformative $500 million+ acquisition by Boston Scientific.[3][4]
Augmenix rode the wave of precision radiation oncology, where rising prostate cancer incidence (millions treated annually via radiotherapy) met demand for side-effect mitigation amid advancing brachytherapy and external beam tech.[1][3] Timing aligned with 2010s reimbursement shifts and hydrogel biomaterials boom, amplified by ASTRO/AUA endorsements and Medicare wins that unlocked U.S. scale.[4] Market forces like aging populations and value-based care favored its proven outcomes, influencing medtech by pioneering organ-sparing devices—now integrated into Boston Scientific's urology portfolio, expanding adjunctive therapies and potentially broader oncology applications.[3][4]
Post-2018 acquisition, Augmenix's SpaceOAR lives on within Boston Scientific, likely driving sustained growth via global distribution, R&D for new indications (e.g., gyno/pancreatic cancers), and integration with robotics/imaging.[3] Trends like AI-guided radiation and biologics will shape its path, amplifying hydrogel's role in personalized therapy. Its legacy elevates organ protection standards, evolving from standalone innovator to cornerstone of large-scale men's health solutions—cementing impact where radiotherapy meets patient quality of life.[1][3]
